Literature DB >> 14601516

Gene therapy for chronic pain.

Joseph C Glorioso1, Marina Mata, David J Fink.   

Abstract

The dorsal horn of the spinal cord represents an attractive site for interventions designed to treat chronic pain, but it has been difficult to identify small molecules that act selectively on pain transmission at the spinal level. One approach is the use of viral vector-mediated gene transfer to achieve focal production and release of short-lived analgesic peptides. Herpes simplex virusbased vectors, expressing proenkephalin delivered by subcutaneous inoculation, transduce neurons of the dorsal root ganglion, leading to release of enkephalin from nerve terminals in dorsal horn to produce an analgesic effect in several models of chronic pain. A clinical trial is set to commence.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14601516

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  5 in total

Review 1.  Herpes simplex viral vectors: late bloomers with big potential.

Authors:  Joseph C Glorioso
Journal:  Hum Gene Ther       Date:  2014-02       Impact factor: 5.695

2.  Pain in amyotrophic lateral sclerosis: a neglected aspect of disease.

Authors:  Chalonda R Handy; Christina Krudy; Nicholas Boulis; Thais Federici
Journal:  Neurol Res Int       Date:  2011-05-03

3.  The 3rd International Meeting on Gene Therapy in Rheumatology and Orthopaedics.

Authors:  Christopher H Evans; Steven C Ghivizzani; Elvire Gouze; John J Rediske; Edward M Schwarz; Paul D Robbins
Journal:  Arthritis Res Ther       Date:  2005-10-28       Impact factor: 5.156

4.  HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain.

Authors:  Shuanglin Hao; Marina Mata; Joseph C Glorioso; David J Fink
Journal:  Mol Pain       Date:  2006-02-17       Impact factor: 3.395

5.  Enkephalin-encoding herpes simplex virus-1 decreases inflammation and hotplate sensitivity in a chronic pancreatitis model.

Authors:  Hong Yang; Terry A McNearney; Rong Chu; Ying Lu; Yong Ren; David C Yeomans; Steven P Wilson; Karin N Westlund
Journal:  Mol Pain       Date:  2008-02-28       Impact factor: 3.395

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.